ipscell.com
Cons Outweigh Potential Pros to BPC Plan on Stem Cells & FDA - The Niche
There is considerable interest in FDA regulatory reform here in the U.S. for stem cell therapies. The goal is to get new treatments to patients faster, but is there a way to do that without sacrificing proven safety and efficacy? You need convincing data on both safety and efficacy or speed becomes dangerous. A group called … Cons Outweigh Potential Pros to BPC Plan on Stem Cells & FDA Read More »
Professor Paul Knoepfler, Ph.D.